HCW Biologics Files 8-K on Shareholder Votes
Ticker: HCWB · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1828673
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
HCW Biologics filed an 8-K for shareholder votes, check for updates on corporate actions.
AI Summary
HCW Biologics Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 14, 2024. The filing details the company's corporate structure and principal executive offices located in Miramar, Florida.
Why It Matters
This filing indicates that HCW Biologics Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- HCW Biologics Inc. (company) — Registrant
- June 14, 2024 (date) — Date of earliest event reported
- June 17, 2024 (date) — Date of report
- Miramar, Florida (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of HCW Biologics Inc. security holders?
The filing indicates that matters were submitted to a vote of security holders as of June 14, 2024, but the specific details of these matters are not provided in the provided text.
When was the 8-K report filed by HCW Biologics Inc.?
The 8-K report was filed on June 17, 2024.
What is the principal executive office address for HCW Biologics Inc.?
The principal executive offices are located at 2929 N. Commerce Parkway, Miramar, Florida, 33025.
What is the Commission File Number for HCW Biologics Inc.?
The Commission File Number for HCW Biologics Inc. is 001-40591.
What is the IRS Employer Identification No. for HCW Biologics Inc.?
The IRS Employer Identification No. for HCW Biologics Inc. is 82-5024477.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-06-17 16:33:01
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
Filing Documents
- hcwb-20240614.htm (8-K) — 45KB
- 0000950170-24-074292.txt ( ) — 159KB
- hcwb-20240614.xsd (EX-101.SCH) — 25KB
- hcwb-20240614_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 14, 2024, HCW Biologics Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders voted on the following two proposals and cast their votes as follows: 1. The Company's stockholders approved the election of one Class III director to serve for a three-year term expiring at the 2027 Annual Meeting of Stockholders, or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Nominee For Withheld Broker Non-Votes Hing C. Wong 24,165,521 1,348,261 2,313,942 The director named under Proposal No. 1 was elected based on the recommendation of the Company's Board of Directors in the Company's 2024 Proxy Statement . 2. The Company's stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: For Against Abstain Broker Non-Votes 27,788,079 7,646 31,999 N/A
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. HCW BIOLOGICS INC. Date: June 17, 2024 By: /s/ Hing C. Wong Hing. C. Wong, Ph.D. Founder and Chief Executive Officer